Breaking News
Get Actionable Insights with InvestingPro+: Start 7 Day FREE Trial Register here
Investing Pro 0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details

United Therapeutics: Tyvaso DPI Approval and Label is 'Best Case Scenario', Brings 'Greater Pipeline Value' and 'Slower Market Share Erosion'

Stock Markets May 24, 2022 08:18AM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
© Reuters. United Therapeutics (UTHR): Tyvaso DPI Approval and Label is 'Best Case Scenario', Brings 'Greater Pipeline Value' and 'Slower Market Share Erosion'

By Vlad Schepkov

Shares of United Therapeutics (NASDAQ:UTHR) quickly climbed the list of Monday, May 23rd's top gainers and most active stocks, finishing the day nearly 12% higher, following midday news the company's Tyvaso DPI got an approval nod from the FDA.

The formal approval was confirmed by the United Therapeutics in this morning's press release, and concluded UTHR's nearly 9-month long battle - Tyvaso had previously gotten a Complete Response Letter (CRL) on October 18, 2021, followed by a 3-month extension to the new PDUFA date - to push its pulmonary hypertension drug candidate through the regulatory finish line.

In what Cowen analyst Joseph Thome sees as a clear win for the company, the FDA denied arguments of a citizen's petition - viewed by many as the main obstacle and reason for the October's CRL - suggesting "excipient FDKP poses a potential risk of acute bronchospasm in patients with chronic lung disease", and approved Tyvaso with a clean label for both pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).

Given the initial CRL, and yet another decision delay that followed, in Cowen's view, "some investors were nervous the therapy would only be approved for PAH, would hold a black box, or would receive a CRL." The analyst is thus highly encouraged by the FDA decision and views "the approval and label as a best case scenario." Cowen models Tyvaso/Tyvaso DPI revenues of $1.9B in 2025 across PAH and PH-ILD and reiterates an "Outperform" rating on UTHR with $250 price target.

Credit Suisse analyst Tiago Fauth also maintains a positive tone over today's announcement, as he believes "today’s favorable approval in both indications establishes the necessary foundation to support the franchise’s long-term tail value, and as well as its future optionality in additional indications."

Fauth now sees "slower long-term market share erosion" and assigns "greater pipeline value to reflect potential label expansion opportunities", as the analyst hikes his price target to $247 from $219, and reiterates an "Outperform" rating on the stock.

Shares of UTHR closed at $210.14 yesterday, merely $8 shy of the stock's all-time high of $218.38, recorded in late 2021.

United Therapeutics: Tyvaso DPI Approval and Label is 'Best Case Scenario', Brings 'Greater Pipeline Value' and 'Slower Market Share Erosion'
 

Related Articles

Asian Stocks Down, Fears of Slowing Economy Linger
Asian Stocks Down, Fears of Slowing Economy Linger By Investing.com - Jul 05, 2022

By Zhang Mengying Investing.com – Asia Pacific stocks were up on Wednesday morning as fears of an economic downturn lingered in the financial market. Japan’s Nikkei 225 fell 1.32%...

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email